Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 5/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | THPO | P40225 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.54 |
| ▸ | ALB | P02768 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.54 |
| ▸ | CDK1 | P06493 | 2/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | ABCB1 | P08183 | 5/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.47 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19863482 | 0.83 | NR1I2 (0.52) | ADORA1CYP1A2CYP3A4CYP2D6PKM | |
| SCHEMBL21348744 | 0.82 | YTHDC1 (0.66) | ADORA1CYP1A2CYP3A4CYP2D6PKM | |
| SCHEMBL23416665 | 0.82 | NR1I2 (0.54) | ADORA1CYP1A2CYP3A4CYP2D6PKM | |
| SCHEMBL11303595 | 0.82 | NR1I2 (0.51) | ADORA1CYP1A2CYP3A4CYP2D6PKM | |
| SCHEMBL10137840 | 0.82 | CDK2 (0.60) | NR1I2ALBPDE4DCDK1CCNB1 | |
| SCHEMBL13751696 | 0.82 | CDK1 (0.58) | NR1I2ALBPDE4DCDK1POLB | |
| SCHEMBL31058758 | 0.80 | POLB (0.61) | ADORA1NR1I2ALBPDE4DADORA3 | |
| SCHEMBL31058754 | 0.80 | CDK2 (0.55) | ADORA1NR1I2ALBPDE4DCDK1 | |
| SCHEMBL31058759 | 0.80 | POLB (0.61) | ADORA1NR1I2ALBPDE4DADORA3 | |
| SCHEMBL13828378 | 0.80 | YTHDC1 (0.66) | ADORA1PDE4DCDK1ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11813278-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-11-14 | — | — | US | disclosed |
| WO-2023178133-A9 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS INC (US) | 2023-09-21 | — | — | US | disclosed |
| WO-2023178133-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| EP-4234565-A2 | HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 | ATEA Pharmaceuticals, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-11147809-B2 | Methods of treating neurofibromatosis with perillyl alcohol | Neonc Technologies, Inc. (US) | 2021-10-19 | — | — | US | disclosed |
| US-20210085681-A1 | COMPOSITIONS AND METHODS FOR TREATING RETINAL DEGRADATION | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2021-03-25 | — | — | US | disclosed |
| WO-2021034373-A1 | CONJUGATES OF GUIDE RNA-CAS PROTEIN COMPLEX | ZHONG MINGHONG (US) | 2021-02-25 | — | — | WO | disclosed |
| US-20210054371-A1 | Conjugates of Guide RNA-Cas Protein Complex | ZHONG MINGHONG (US) | 2021-02-25 | — | — | US | disclosed |
| US-20200222442-A1 | 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT | Atea Pharmaceuticals, Inc. (US) | 2020-07-16 | — | — | US | disclosed |
| CN-101429215-A | Process for selectively producing 1-phosphorylated sugar derivative anomer and process for producing nucleoside | MITSUI CHEMICALS INC (JP) | 2009-05-13 | — | — | CN | disclosed |
| EP-1573019-B1 | STEREOSELECTIVE PROCESS FOR THE PRODUCTION OF DIOXOLANE NUCLEOSIDE ANALOGUES | SHIRE BIOCHEM INC (CA) | 2009-01-14 | — | — | EP | disclosed |
| US-7442813-B2 | Process for producing dioxolane nucleoside analogues | SHIRE BIOCHEM INC. (CA) | 2008-10-28 | — | — | US | disclosed |
| US-7442813-B2 | Process for producing dioxolane nucleoside analogues | SHIRE BIOCHEM INC. (CA) | 2008-10-28 | — | — | US | disclosed |
| US-20070197784-A1 | Process for producing dioxolane nucleoside analogues | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-23 | — | — | US | disclosed |
| US-20070197784-A1 | Process for producing dioxolane nucleoside analogues | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-23 | — | — | US | disclosed |
| CN-1867576-A | Alpha-1-phosphorylated-2-deoxy-2-fluoroarabinoside and process for producing 2' -deoxy-2' -fluoro-beta-D-arabinonucleosid e | YAMASA CORP (JP) | 2006-11-22 | — | — | CN | disclosed |
| CN-1238519-C | Process for producing nucleoside compound | MITSUI CHEMICALS INC (JP) | 2006-01-25 | — | — | CN | disclosed |
| CN-1372564-A | Process for selectively preparing anomers of 1-phosphorylated sugar derivatives and process for preparing nucleosides | MITSUI CHEMICALS INC (JP) | 2002-10-02 | — | — | CN | disclosed |
| CN-1361827-A | Process for producing nucleoside compound | MITSUI CHEMICALS INC (JP) | 2002-07-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | ADORA1 1163/4885CYP1A2 3088/4885CYP3A4 3622/4885 |
| US-11147809-B2 | Methods of treating neurofibromatosis with perillyl alcohol | PMP22, CHAT, REL | ADORA1 4722/4885CYP1A2 2160/4885CYP3A4 3770/4885 |
| US-20200222442-A1 | 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT | NSUN2, ADAR, NSUN3 | ADORA1 115/4885CYP1A2 2467/4885CYP3A4 2594/4885 |
| US-11813278-B2 | Highly active compounds against COVID-19 | PNP, ACE2, MTAP | ADORA1 132/4885CYP1A2 1898/4885CYP3A4 1696/4885 |
| US-20210085681-A1 | COMPOSITIONS AND METHODS FOR TREATING RETINAL DEGRADATION | ALDH1A2, UNG, DNASE1L3 | ADORA1 1722/4885CYP1A2 4673/4885CYP3A4 4746/4885 |
| US-20210054371-A1 | Conjugates of Guide RNA-Cas Protein Complex | SARNP, SLIRP, NSUN3 | ADORA1 3019/4885CYP1A2 4752/4885CYP3A4 4580/4885 |
| US-20070197784-A1 | Process for producing dioxolane nucleoside analogues | NUDT1, DPYD, DUT | ADORA1 40/4885CYP1A2 801/4885CYP3A4 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.